Latest immunotherapy news
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer
posted August 6th
by modernClinician Editorial Team
by modernClinician Editorial Team
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment
posted August 3rd
by modernClinician Editorial Team
by modernClinician Editorial Team
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine
posted July 28th
by modernClinician Editorial Team
by modernClinician Editorial Team
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma
posted July 23rd
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Definition of Functional High-Risk Multiple Myeloma Updated in Era of Combo Therapy 
Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS 
Aglatimagene Besadenovec + Valacyclovir Ups DFS in Localized Prostate Cancer 
Subset of Patients With Follicular Lymphoma Can Achieve Cure With CHOP-Based Chemoimmunotherapy Related Articles
Perioperative Enfortumab Vedotin + Pembrolizumab Tied to Improved Outcomes With Bladder Cancer 
Guidelines Issued for Management of Acute Lymphoblastic Leukemia in Teens, Young Adults 
Presurgical Pembrolizumab Beneficial for Desmoplastic Melanoma Monthly Specialist Briefings
Stay Connected
